Effectiveness of Rituximab in Severe Wegener’s Granulomatosis: Report of Two Cases and Review of the Literature

Joaquim Oristrell*, Guillermina Bejarano, Rosa Jordana, Manuel Monteagudo, Begoña Marí, Arnau Casanovas, Carles Tolosa
Internal Medicine Service, Hospital de Sabadell, Corporació Parc Taulí, Universitat Autònoma de Barcelona (UAB), Spain

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 1125
Abstract HTML Views: 1192
PDF Downloads: 234
Total Views/Downloads: 2551
Unique Statistics:

Full-Text HTML Views: 459
Abstract HTML Views: 709
PDF Downloads: 171
Total Views/Downloads: 1339

© Oristrell et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Corporació Parc Taulí, Parc Tauli s/n, 08208 Sabadell, Barcelona, Spain; Tel: + 34-937 458 252; Fax: 34-937 160 646; E-mail:


We hereby describe the satisfactory evolution of rituximab treatment in two patients with Wegener’s granulomatosis (WG). Rituximab was indicated for refractoriness to standard treatment in one case and life-threatening myelotoxicity due to alkylating agents in the other. A brief review of previous experience with the use of rituximab in the treatment of WG is presented.

Keywords: Rituximab, Wegener’s granulomatosis, rescue treatment..